SP-563

SP-563 is an investigational vector-drug conjugate (VDC) currently in preclinical development by Stamford Pharmaceuticals for the treatment of non-muscle invasive bladder cancer (NMIBC). Developed as part of the company's proprietary VDC platform, SP-563 is designed to utilize a vector-based delivery mechanism to transport a therapeutic payload directly to malignant cells within the bladder. While specific details regarding the molecular target and the nature of the conjugated payload have not been publicly disclosed, the VDC approach aims to enhance therapeutic efficacy while minimizing systemic exposure and associated side effects. The program represents a targeted expansion of Stamford Pharmaceuticals' pipeline into urological oncology.